JT Terminates Exclusive License Agreement with EirGen Pharma for Calcifediol Extended-release Capsules (JTT-762)

FOR IMMEDIATE RELEASE
Tokyo, May 25, 2021

JT Terminates Exclusive License Agreement with EirGen Pharma for Calcifediol
Extended-release Capsules (JTT-762)

Japan Tobacco Inc. (JT) (TSE:2914) announced today that the company will discontinue
the development of JTT-762 (RAYALDEE® Calcifediol Extended-release Capsules). JT
also announced the termination of the license agreement with EirGen Pharma Ltd.
(EirGen Pharma) .

JTT-762 is a novel extended-release formulation of the prohormone of calcitriol, the
active form of vitamin D 3 , which is approved to treat secondary hyperparathyroidism
(SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D
insufficiency in the U.S. and 11 European countries. JT’s decision to discontinue
development of JTT-762 follows a comprehensive reconsideration of its development
pipeline.

The effects of this termination of the exclusive license agreement on JT’s business
performance in this fiscal year will be immaterial.

About EirGen Pharma Ltd.
EirGen Pharma Ltd., established in 2005, is a world-leader in the development, registration,
manufacturing and supply of high-potency pharmaceutical products to global markets. The company
is headquartered Waterford, Ireland.
For more information, visit www.eirgen.com.

###

Japan Tobacco Inc. is a leading international tobacco company with operations in more than 130 countries. With
approximately 58,000 employees, it manufactures and sells some of the world’s best-known brands including Winston,
Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets
its heated tobacco products under the Ploom brand and various e-cigarette products under its Logic brand. The Group
is also present in the pharmaceutical and processed food businesses.
For more information, visit https://www.jt.com/ .



Contact for Japan Tobacco Inc.:
Dinesh Babu Thotakura, General Manager
Media and Investor Relations Division
Japan Tobacco Inc. Tokyo: +81-3-6636-2026
E-mail: jt.media.relations@jt.com

2218